Press Releases Keyword Search Year None20202019201820172016201520142013 May 7, 2020 Editas Medicine Announces First Quarter 2020 Results and Update April 30, 2020 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update April 29, 2020 Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers March 4, 2020 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 February 26, 2020 Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update February 19, 2020 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update January 13, 2020 Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference January 13, 2020 Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer January 10, 2020 Editas Medicine Reports Inducement Grants to New Chief Financial Officer January 9, 2020 Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last »
April 30, 2020 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
April 29, 2020 Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
March 4, 2020 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
February 19, 2020 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update
January 13, 2020 Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
